{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:24:48Z","timestamp":1787682288581,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.clinthera.2021.01.008","type":"journal-article","created":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T04:59:32Z","timestamp":1612587572000},"page":"594-601.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Interindividual Variability in the Pharmacodynamic and Pharmacokinetic Characteristics of Recombinant Human Insulin and Insulin Aspart"],"prefix":"10.1016","volume":"43","author":[{"given":"Ting","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtao","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0103-0087","authenticated-orcid":false,"given":"Yerong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.01.008_bib1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2337\/diacare.7.2.188","article-title":"Insulin pharmacokinetics","volume":"7","author":"Binder","year":"1984","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2021.01.008_bib2","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1089\/152091502320798312","article-title":"Variability of insulin absorption and insulin action","volume":"4","author":"Heinemann","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.clinthera.2021.01.008_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1262-3636(07)70160-X","article-title":"Reproducibility and variability in the action of injected insulin","volume":"31","author":"Gin","year":"2005","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clinthera.2021.01.008_bib4","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.2337\/diacare.22.9.1501","article-title":"Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects","volume":"22","author":"Mudaliar","year":"1999","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2021.01.008_bib5","series-title":"Insulin\u2014Pharmacology, Therapeutic Regimens, and Principles of Intensive Insulin Therapy","author":"Donner","year":"2019"},{"key":"10.1016\/j.clinthera.2021.01.008_bib6","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2337\/diacare.13.9.923","article-title":"Monomeric insulins and their experimental and clinical implications","volume":"13","author":"Brange","year":"1990","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2021.01.008_bib7","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.2337\/diacare.21.11.1910","article-title":"Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart","volume":"21","author":"Heinemann","year":"1998","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2021.01.008_bib8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/193229680800200406","article-title":"Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin","volume":"2","author":"Hompesch","year":"2008","journal-title":"J\u00a0Diabetes Sci Technol"},{"key":"10.1016\/j.clinthera.2021.01.008_bib9","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.diabres.2006.11.011","article-title":"Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels","volume":"77","author":"Woerle","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2021.01.008_bib10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1463-1326.2012.01580.x","article-title":"The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences","volume":"14","author":"Home","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2021.01.008_bib11","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13300-019-00732-w","article-title":"Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes","volume":"11","author":"Nicolucci","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2021.01.008_bib12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.20452\/pamw.2705","article-title":"Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis","volume":"125","author":"Wojciechowski","year":"2015","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.clinthera.2021.01.008_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/dia.2011.0299","article-title":"A\u00a0comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study","volume":"14","author":"Ma","year":"2012","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.clinthera.2021.01.008_bib14","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/A:1025594110558","article-title":"Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin","volume":"30","author":"\u00d8sterberg","year":"2003","journal-title":"J\u00a0Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2021.01.008_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1463-1326.2012.01677.x","article-title":"Insulin aspart has a shorter duration of action than human insulin over a wide dose-range","volume":"15","author":"Nosek","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2021.01.008_bib16","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/MJT.0000000000001089","article-title":"Biosynthetic human insulin and insulin analogs","volume":"27","author":"Rodbard","year":"2020","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2021.01.008_bib17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2337\/dc16-1771","article-title":"Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1)","volume":"40","author":"Russell-Jones","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2021.01.008_bib18","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.domaniend.2011.05.001","article-title":"Evaluation of commercially available assays for the measurement of equine insulin","volume":"41","author":"Tinworth","year":"2011","journal-title":"Domest Anim Endocrinol"},{"key":"10.1016\/j.clinthera.2021.01.008_bib19","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1039\/C9AN00112C","article-title":"Insulin: a review of analytical methods","volume":"144","author":"Shen","year":"2019","journal-title":"The Analyst"},{"issue":"1\u20132","key":"10.1016\/j.clinthera.2021.01.008_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2013.07.007","article-title":"Comparison of bioanalytical methods for the quantitation of PEGylated human insulin","volume":"396","author":"de Dios","year":"2013","journal-title":"J\u00a0Immunol Methods"},{"issue":"4, Part 2","key":"10.1016\/j.clinthera.2021.01.008_bib21","doi-asserted-by":"crossref","first-page":"4S","DOI":"10.1016\/S1262-3636(05)88263-1","article-title":"Subcutaneous insulin: pharmacokinetic variability and glycemic variability","volume":"31","author":"Guerci","year":"2005","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.clinthera.2021.01.008_bib22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejps.2008.10.018","article-title":"Absorption kinetics of insulin after subcutaneous administration","volume":"36","author":"S\u00f8eborg","year":"2009","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.clinthera.2021.01.008_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejps.2014.05.010","article-title":"Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms","volume":"62","author":"Rasmussen","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.clinthera.2021.01.008_bib24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1463-1326.2003.00266.x","article-title":"Limitations to subcutaneous insulin administration in type 1 diabetes","volume":"5","author":"Chen","year":"2003","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2021.01.008_bib25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2337\/diab.22.7.507","article-title":"Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects","volume":"22","author":"Olefsky","year":"1973","journal-title":"Diabetes"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182100014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182100014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:09Z","timestamp":1758963309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182100014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S014929182100014X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interindividual Variability in the Pharmacodynamic and Pharmacokinetic Characteristics of Recombinant Human Insulin and Insulin Aspart","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}